By VETTAPHARMA reporter: The U.S. Food and Drug Administration (FDA) approved a set of safety-related labeling changes for ZILBRYSQ (zilucoplan sodium) under New Drug Application NDA-216834, reflecting newly available safety information intended to enhance patient and healthcare provider awareness of important risks and monitoring resources associated with the drug. ZILBRYSQ® (zilucoplan) is currently indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
According to the FDA’s Drug Safety-related Labeling Changes (SrLC) database, the updated labeling includes new information in the “Use in Specific Populations” section that establishes a pregnancy exposure registry for women exposed to ZILBRYSQ during pregnancy and/or breastfeeding. This registry is intended to support collection of data on pregnancy outcomes following exposure, and healthcare providers and patients may contact UCBCares for enrollment or additional information.
In addition to the pregnancy registry information, patient counseling and medication guide sections were revised to reflect the added safety detail. Among these updates:
- Patients are advised that ZILBRYSQ may lower the ability of the immune system to fight infections, particularly serious meningococcal infections caused by Neisseria meningitidis bacteria, which can be life-threatening if not promptly recognized and treated.
- The revised labeling strongly emphasizes that patients complete or update meningococcal vaccinations at least two weeks before starting ZILBRYSQ therapy. For patients who must begin treatment immediately and lack up-to-date vaccination, antibiotic prophylaxis should be provided.
- Patients must also be instructed to carry a Patient Safety Card during and for up to two months after ZILBRYSQ treatment. The card outlines signs and symptoms of serious infection that warrant urgent medical evaluation.
- The updated Patient Counseling Information advises patients and/or caregivers to read FDA-approved patient labeling (Medication Guide and Instructions for Use) and to be informed of the need to complete or update meningococcal vaccinations at least 2 weeks prior to receiving the first dose of ZILBRYSQ or receive antibacterial drug prophylaxis if ZILBRYSQ treatment must be initiated immediately and they have not been previously vaccinated, as well as the requirement to seek immediate medical attention if specific signs or symptoms occur.
- In the Medication Guide, underlined additions state that ZILBRYSQ may lower the ability of your immune system to fight infections and increases your chance of getting serious meningococcal infections, instructing patients that they must complete or update your meningococcal vaccine(s) at least 2 weeks before your first dose and receive antibiotics if treatment must start right away, and to carry a Patient Safety Card describing symptoms prompting urgent care.
The FDA’s comprehensive revisions serve to clarify risk factors, bolster preventive practices, and ensure that patients and their clinicians are better informed about infectious risks and pregnancy considerations associated with ZILBRYSQ therapy.
Source credit:
- U.S. Food and Drug Administration. (n.d.). Drug Safety-related Labeling Changes (SrLC) for ZILBRYSQ (zilucoplan sodium), NDA-216834. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
